Attack frequency and associated factors in hereditary angioedema patients: a single-centre experience.

IF 1.4 4区 医学 Q3 ALLERGY
Postepy Dermatologii I Alergologii Pub Date : 2025-02-01 Epub Date: 2024-11-06 DOI:10.5114/ada.2024.144488
Makbule Seda Bayrak Durmaz, Nurgul Sevimli
{"title":"Attack frequency and associated factors in hereditary angioedema patients: a single-centre experience.","authors":"Makbule Seda Bayrak Durmaz, Nurgul Sevimli","doi":"10.5114/ada.2024.144488","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Hereditary angioedema (HAE) significantly affects patients' quality of life due to its life-threatening potential and the unpredictability of attacks.</p><p><strong>Aim: </strong>To determine strategic goals to reduce the frequency of attacks and improve the quality of life by evaluating the attack triggers, attack management strategies, and medication use attitudes of HAE patients treated in our clinic.</p><p><strong>Material and methods: </strong>Patients who were followed up in our clinic with a diagnosis of HAE in 2022-2023 were included in the study. Patient data were obtained by retrospective scanning of file records.</p><p><strong>Results: </strong>The analysis included 23 HAE patients with an average age of 34.7 years, predominantly female (60.9%). In the patients' family history, there was a high prevalence of HAE (95.7%) and HAE-related death (73.9%). The median duration of HAE diagnostic delay was 9 years (0-50). A significant positive correlation was found between patient age and the duration of diagnostic delay (<i>r</i> = 0.575; <i>p</i> = 0.004). The majority of patients were aware of acute attack triggers and contraindicated medications (91.3%, 70%, respectively). Gastrointestinal, facial, and limb symptoms were common, with emotional stress identified as the leading trigger. The median monthly attack frequency was 6 (1-10), with nearly half experiencing more frequent episodes. Response times to on-demand treatment for icatibant were less than 30 min in 52.2% of patients. Despite experiencing frequent attacks, many patients exhibited pharmacophobia, leading to reluctance towards second-line long-term prophylactic (LTP) therapy.</p><p><strong>Conclusions: </strong>The high frequency of attacks in our patients was related to the lack of use of LTP agents and personal life stress. Despite severe attacks and a family history of HAE-related deaths, pharmacophobia to LTP was common, with pharmacophobia resulting from side effects of second-line LTP agents. Our findings highlight the need for our patients to have access to psychosocial support programs and first-line LTP agents.</p>","PeriodicalId":54595,"journal":{"name":"Postepy Dermatologii I Alergologii","volume":"42 1","pages":"75-82"},"PeriodicalIF":1.4000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921922/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Postepy Dermatologii I Alergologii","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5114/ada.2024.144488","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/6 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Hereditary angioedema (HAE) significantly affects patients' quality of life due to its life-threatening potential and the unpredictability of attacks.

Aim: To determine strategic goals to reduce the frequency of attacks and improve the quality of life by evaluating the attack triggers, attack management strategies, and medication use attitudes of HAE patients treated in our clinic.

Material and methods: Patients who were followed up in our clinic with a diagnosis of HAE in 2022-2023 were included in the study. Patient data were obtained by retrospective scanning of file records.

Results: The analysis included 23 HAE patients with an average age of 34.7 years, predominantly female (60.9%). In the patients' family history, there was a high prevalence of HAE (95.7%) and HAE-related death (73.9%). The median duration of HAE diagnostic delay was 9 years (0-50). A significant positive correlation was found between patient age and the duration of diagnostic delay (r = 0.575; p = 0.004). The majority of patients were aware of acute attack triggers and contraindicated medications (91.3%, 70%, respectively). Gastrointestinal, facial, and limb symptoms were common, with emotional stress identified as the leading trigger. The median monthly attack frequency was 6 (1-10), with nearly half experiencing more frequent episodes. Response times to on-demand treatment for icatibant were less than 30 min in 52.2% of patients. Despite experiencing frequent attacks, many patients exhibited pharmacophobia, leading to reluctance towards second-line long-term prophylactic (LTP) therapy.

Conclusions: The high frequency of attacks in our patients was related to the lack of use of LTP agents and personal life stress. Despite severe attacks and a family history of HAE-related deaths, pharmacophobia to LTP was common, with pharmacophobia resulting from side effects of second-line LTP agents. Our findings highlight the need for our patients to have access to psychosocial support programs and first-line LTP agents.

遗传性血管性水肿患者的发作频率及相关因素:单中心研究
遗传性血管性水肿(HAE)由于其潜在的生命危险和发作的不可预测性而显著影响患者的生活质量。目的:通过评估在我院治疗的HAE患者的发作诱因、发作管理策略和用药态度,确定降低发作频率和改善生活质量的策略目标。材料和方法:在我们诊所随访的2022-2023年诊断为HAE的患者纳入研究。通过回顾性扫描档案记录获得患者资料。结果:分析纳入23例HAE患者,平均年龄34.7岁,以女性为主(60.9%)。在患者的家族史中,有较高的HAE患病率(95.7%)和HAE相关死亡(73.9%)。HAE诊断延迟的中位持续时间为9年(0-50年)。患者年龄与诊断延迟时间呈显著正相关(r = 0.575;P = 0.004)。大多数患者知道急性发作触发因素和禁忌症药物(分别为91.3%和70%)。胃肠道、面部和肢体症状很常见,情绪压力被确定为主要诱因。每月发作频率中位数为6次(1-10次),其中近一半的发作频率更高。52.2%的患者对依需治疗icatibant的反应时间小于30分钟。尽管频繁发作,但许多患者表现出药物恐惧症,导致不愿接受二线长期预防(LTP)治疗。结论:本组患者的高发作频率与LTP药物使用不足和个人生活压力有关。尽管有严重的发作和与hae相关的死亡家族史,但对LTP的药物恐惧症是常见的,药物恐惧症是由二线LTP药物的副作用引起的。我们的研究结果强调,我们的患者需要获得社会心理支持计划和一线LTP药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.60
自引率
7.10%
发文量
107
审稿时长
6-12 weeks
期刊介绍: Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii is a bimonthly aimed at allergologists and dermatologists.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信